Penmenvy 可预防脑膜炎球菌血清型 A、B、C、W 和 Y。一种疫苗可广泛覆盖血清群，减少注射次数，有助于提高疫苗接种率，保护更多美国青少年和年轻人。 葛兰素史克公司 (LSE/NYSE: GSK) 宣布，美国食品药品监督管理局 (FDA) ...

FDA 预计将对帕金森病、创伤后应激障碍和 NF1 相关丛状神经纤维瘤的治疗方法以及两种新疫苗做出决定。 处方药使用者付费法案 (PDUFA)日期是指美国食品药品管理局 (FDA) 规定的审查新药申请 (NDA)或生物制品许可申请 (BLA)并最终决定是否批准上市的截止日期。审查期通常为药品申请被该机构接受后的 10 个月。对于优先审查的药品，审查期缩短为申请接受后的 6 个月。 FDA 正在审查 ...

Immune responses against serogroups A, C, W, and Y were noninferior between the MenABCWY and MenACWY-CRM vaccines in young adults and adolescents.

GSK日前宣布，美国FDA已批准其组合疫苗Penmenvy（MenABCWY）上市，在10~25岁人群中使用。这款疫苗针对脑膜炎球菌中最常见的5大血清群，它们通常是导致 ...

MenABCWY covers five of the six serogroups that cause most disease worldwide, with the B, C, and Y strains responsible for most cases of invasive meningococcal disease (IMD) encountered in the US.

GSK’s MenABCWY vaccine is an injectable suspension intended for intramuscular use. It comes with a vial of lyophilised MenACWY powder, mixed with a prefilled syringe of MenB liquid before use.

At their meeting on February 26, 2025, the CDC's Advisory Committee on Immunization Practices (ACIP) is anticipated to vote on guidelines for the recommended use of GSK's MenABCWY vaccine in ...

The latest data on its MenABCWY vaccine – which covers all five meningococcal strains in one go as an alternative to separate vaccinations – showed that the shot met all 11 of its primary ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine) for use in individuals aged 10 through ...